HCP Resources

Glaukos Practice Resource Hub (Printed Materials)

To order print versions of our practice marketing materials, including educational resources on keratoconus and FDA-approved cross-linking, please visit the Glaukos Practice Resource Hub. The materials available include the following:

  • Living With Keratoconus Patient Brochure (English & Spanish)
  • Patient Brochure Stand
  • Patients Guide to Insurance Coverage of Cross-Linking Handout
  • Keratoconus Signs & Symptoms Handout
  • Referring Physicians Brochure
  • Cross-Linking Practice Marketing Kit*
    • (100) Living With Keratoconus Patient Brochure
    • (1) Patient Brochure Stand
    • (100) Patients Guide to Insurance Coverage of Cross-Linking Handout
    • (1) Living With KC Wirebound Marketing Book

Click the link below to order your printed materials today!

Order prints

*The digital version of the Cross-Linking Practice Marketing Kit is available upon request. Please contact us today.

Digital downloads

In addition to printed materials, you can also download digital versions of many of our educational resources. Click the links below to view and download any of the available materials.

Manuals

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epethelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Reference

1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016